ELOX Financials

Income Statement
MetricQ2 2026Q1 2026Q2 2025Q1 2025Q4 2023
Revenue
0
0
0
0
Cost of Revenue
0
0
0
0
0
Gross Profit
0
0
0
0
Operating Expenses
4.5M
+17.3%
3.8M
+139.9%
1.6M
+29.5%
1.2M
R&D
2.8M
+71.2%
1.7M
+84.7%
898.0K
+76.1%
510.0K
SG&A
1.6M
-24.6%
2.1M
+212.3%
684.0K
-3.9%
712.0K
Operating Income
-4450000
-17.3%
-3795000
-139.9%
-1582000
-29.5%
-1222000
EBITDA
-4450000
-17.3%
-3795000
-139.9%
-1582000
-29.5%
-1222000
0
Net Income
-4502000
-19.9%
-3754000
-98.5%
-1891000
-10.6%
-1709000
EPS (Basic)
$-0.66
-725.0%
$-0.08
+98.5%
$-5.45
-1111.1%
$-0.45
EPS (Diluted)
$-0.66
-725.0%
$-0.08
+98.5%
$-5.45
-1111.1%
$-0.45
Shares (Diluted)
6.8M
-85.9%
48.2M
+13793.4%
347.0K
-90.9%
3.8M
+20.6%
3.2M
Eloxx Pharmaceuticals (ELOX) — Financials